Clinical Trial Update: Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects [Phase 3]

View source ↗

Summary

Phase 3 trial comparing atomoxetine to placebo for cognitive late effects in cancer patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Cognitive Late Effects

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Temple University | Conditions: Cancer, Cognitive Late Effects | Phase 3 | Status: WITHDRAWN